Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$30.60M$30.60Mderivedno prior Q4 2023 on file Net Income-$21.87M-$21.87MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$22,565,000−14.3% Operating Incomederived$27,818,000N/M Operating Cash Flowderived$1,582,000−56.5% Free Cash Flowderived$275,000−84.7% Margins · derivedGross margin73.7%
Operating margin90.9%
Net margin-71.4%
ended Dec 31, 2024 · filed Mar 17, 2025 · 76 d after period end